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The receptor for human T-cell leukemia virus type 1 (HTLV-1) was found to be expressed on a broad range of cell lines
derived from multiple species. Receptor expression was assessed using human immunodeficiency virus type 1 particles,
pseudotyped with the HTLV-1 envelope glycoprotein, and expressing luciferase under the control of an SV40 enhancer and
promoter. Infection by pseudotyped virus was blocked with neutralizing antibodies to HTLV-1, and infection was dependent
on the presence of the cleavage and fusogenic sequences in the envelope protein precursor. Trypsin treatment of
susceptible target lymphocytes reduced entry. Entry was partially resistant to ammonium chloride. © 2000 Academic Press
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HINTRODUCTION
Human T cell leukemia virus type 1 (HTLV-1) is the
etiological agent of adult T cell leukemia/lymphoma and
HTLV-associated myelopathy, occurring in 1–10% of in-
fected individuals (Hollsberg and Hafler, 1996; Ratner
and Poiesz, 1988). It is endemic in southern Japan, the
Caribbean islands, and parts of South America and Af-
rica and is frequently found in intravenous drug abusers
in North America. The homologous virus, HTLV-2, al-
though not clearly associated with a specific disease, is
widespread among Native Americans, as well as intra-
venous drug abusers. Several simian T-cell leukemia
viruses are found to be highly related to HTLV-1 or -2,
present in a wide range of primates, and associated with
lymphoma in primate centers.
The HTLV-1 envelope protein is synthesized as a 462-
amino-acid, 62-kDa precursor glycoprotein that is
cleaved, oligomerized, and glycosylated in the endoplas-
mic reticulum and Golgi (Paine et al., 1994; Pique et al.,
1990). It is expressed on the surface of the infected cell
and the virion as a complex of a 289-amino-acid, 46-kDa
surface glycoprotein and a 176-amino-acid, 21-kDa trans-
membrane protein (TM). Analogous to other retroviruses,
it is assumed that the surface glycoprotein binds to a
cellular receptor, leading to conformational activation of
the fusion sequence in the TM (Weiss et al., 1985). The
nature of the cellular receptor and cellular entry is poorly
understood.
HTLV-1 and -2 and simian T-cell leukemia virus are
thought to share a receptor, based on studies of mutual
interference for infection (Sommerfelt and Weiss, 1990).w
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41Several candidate proteins have been proposed as the
receptor for HTLV-1 or an adhesion molecule that pro-
motes infection, including interleukin (IL)-2 receptor-a
(Lando et al., 1983), 71-kDa heat shock protein (Sagara et
al., 1998), vascular cell adhesion molecule-1 (Hildreth et
al., 1997), a 40- to 70-kDa glycoprotein designated C33
(Imai et al., 1992), an 80-kDa glycoprotein analog of
intercellular adhesion molecule-3 (Agadjanyan et al.,
1994), and a 30- to 31-kDa protein (Gavalchin et al., 1995).
In the current work, we used a highly sensitive
pseudotype assay, first reported by Sutton and Littmann
(1996), to demonstrate the pattern of expression of the
HTLV-1 receptor, to examine several putative molecules as
potential receptors, and to address the mode of viral entry.
RESULTS
Viral pseudotypes
A sensitive, quantitative single-cycle assay of HTLV-1
infection used viral pseudotypes of HIV particles with the
HTLV envelope protein (Fig. 1). Negative and positive
controls included nonpseudotyped particles and parti-
cles pseudotyped with the vesicular stomatitis virus gly-
coprotein (VSV-G), whose receptor is constitutively ex-
pressed on a wide array of cell types of various species
(Friedmann and Yee, 1995). The HIV genome used in this
study includes the luciferase gene under the regulation
of the SV40 promoter in place of the HIV-1 env gene
(HIVLuc1Env2, Fig. 1). Producer 293T cells were trans-
fected with HIVLuc1Env2 and Env expression plasmids,
induced with butyrate, and after 60–72 h, pseudotyped
viral particles were harvested from the culture superna-
tants, filtered through a 0.22-mm filter, and titered by an
IV-1 p24 antigen ELISA. Target cells were then infected
ith pseudotyped particles, and after 48 h, luciferase
ssays were performed to measure infection.
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42 TREJO AND RATNERThe quantitative characteristics of the assay were
evaluated with increasing amounts of HTLV-1 envelope
pseudotyped particles. Using 90, 460, 925, and 2700 ng
of HTLV-1 envelope pseudotyped particles to infect HeLa
cells, 500, 11,000, 20,000, and 52,000 light units, respec-
tively, were measured (not shown). The luciferase activ-
ities reported are linear through this range. Using 8000
ng of nonpseudotyped particles, fewer than 100 light
units was seen in these cells.
Expression of the HTLV-1 receptor
Pseudotyped virus particles were used to infect a wide
variety of cell lines, including cell lines previously shown
to be highly susceptible to HTLV-1 infection (human HOS,
293T, HeLa, and BJAB WH cells), as well as cell lines
previously reported not to be susceptible to HTLV-1 in-
fection (human BJAB CC84 and U87-MG cells, mouse
C127/LT cells, pig MPK cells, hamster CHO cells, mon-
key CV-1 cells, rat NRK cells, bat Tb1lu cells, quail QM7
cells, and bovine MDBK cells; Fig. 2) (Copeland et al.,
1994; Li et al., 1996; Sommerfelt et al., 1988). Using
articles pseudotyped with the HTLV-1 envelope, all cell
ines, with the exception of MDBK cells, could be in-
ected, although the levels of luciferase activity varied
mong cell lines between 6 3 103 and 3 3 107 light units
FIG. 1. Infection with viral pseudotypes. The schematic shows t
HIVLuc1Env2 plasmid with or without a plasmid expressing the HTLV
particles were harvested from the cell culture supernatant, purified throu
ere used to infect susceptible target cells for 3 h, and after an addit(Fig. 2A). All cell lines could be infected with VSV-G
pseudotyped particles (Fig. 2B). Ratios of activity of par-ticles with HTLV-1 envelope versus those with VSV-G
varied between 0.001 and 1.3 for the infectable cell lines,
suggesting that there is significant variability in the level
of HTLV-1 receptor on these cell lines. Limitations in
assay sensitivity in previous studies may have been
responsible for the failure to identify low but significant
levels of HTLV-1 receptor activity.
The ratio of activity on MDBK cells of HTLV-1 envelope
versus VSV-G pseudotyped particles was ,0.0003. Al-
though, a low level of HTLV-1 receptor expression on these
cells cannot be ruled out, the level appears to be 4- to
4400-fold lower than that of the other cell lines tested.
Characterization of the HTLV-1 receptor
To examine the specificity of the interaction of HTLV-1
envelope pseudotyped particles with HOS cells, prein-
cubation of particles with pooled anti-gp45 envelope
neutralizing antibodies was examined (Fig. 3). A 97%
decrease in luciferase activity was seen with the HTLV-1
envelope pseudotyped particles, but no effect was seen
on infection by VSV-G pseudotyped particles (Fig. 3A).
Antibodies to heat shock protein 71 were also exam-
ined, in light of recent reports that this moiety may serve
as the receptor for HTLV-1 (Sagara et al., 1998). However,
these antibodies had no effects on infection by HTLV-1
l pseudotypes were produced from 293T cells transfected with a
elope protein or VSV-G glycoprotein. After 60–72 h, pseudotyped viral
.22-mm filter, and titered by a p24 antigen ELISA. The resultant particles
8 h of incubation, luciferase assays were performed.hat vira
-1 envenvelope or VSV-G pseudotyped particles (Fig. 3A). In
this experiment, an antibody to platelet-derived growth
a
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43HTLV RECEPTORfactor-b receptor was used as an additional negative
control, and no alteration in infection was seen (Fig. 3A).
An additional control to examine the specificity of
HTLV-1 receptor activity used a mutant envelope precur-
sor protein that is noncleavable and nonfusogenic. For
this purpose, the RSRR cleavage site in the gp62 precur-
sor protein was mutated to RSRT, and the N-terminal
hydrophobic AVP residues of TM were converted to AED.
Both of these alterations have been shown to disrupt
fusion activity of the HIV-1 envelope precursor protein
(Stein et al., 1987). This plasmid was designated pHTE-
1DSUTM, and the mutant precursor envelope protein
was found by immunoblotting to be stably expressed in
the transfected cells and the resultant pseudotyped virus
particles (not shown). Nevertheless, the infectivity of par-
ticles pseudotyped with the mutant envelope precursor
FIG. 2. The HTLV receptor is widely expressed on diverse cell types o
ctivity, of a variety of cell lines incubated with virus particles pseudo
lycoprotein produced from pHCMV-G. Columns represent the mean lprotein was 0.0015% of that of the properly processed
form of the HTLV-1 envelope glycoprotein (Fig. 3B).Because the HTLV-1 receptor is widely expressed, we
also examined whether it was a cell-surface protein. For
this purpose, phytohemagglutin-stimulated human pe-
ripheral blood mononuclear cells (PBMCs) were used,
because their cell surface proteins were highly suscep-
tible to trypsin treatment. Infection of trypsin-treated and
nontreated PBMCs was examined with HTLV-1 envelope
pseudotyped particles (Fig. 4). Positive and negative con-
trols in this study included particles pseudotyped with
the HIV-1 envelope, which uses a protein receptor and
coreceptor at the cell surface, and VSV-G, which does
not use a protein for binding (Dimitrov, 1997). Trypsin
treatment of PBMCs reduced HTLV-1 receptor activity by
75% and HIV-1 receptor activity by 85%, whereas no
effect was seen on VSV-G receptor activity. Although this
study does not rule out the presence of a second trypsin-
nt species. Infection titers, recorded as relative light units of luciferase
ith (A) the HTLV-1 envelope produced from pHTE-1 or (B) the VSV-G
f infection of duplicate assays, and the range of values is indicated.f differe
typed wresistant HTLV-1 receptor on PBMCs, it indicates that the
predominant activity is trypsin sensitive.
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44 TREJO AND RATNERMode of HTLV-1 entry
Retroviruses have been found to enter susceptible
target cells via pH-sensitive or pH-insensitive endocytic
pathways or via pH-insensitive fusion of the viral lipid
envelope with the plasma membrane (Kielian and
Jungerwirth, 1990). In this experiment, a HeLa cell variant
was used, designated Magi-CCR5 cells, to also test
HIV-1 as a negative control, because HIV-1 enters sus-
ceptible target cells via a pH-insensitive fusion process
FIG. 3. Specificity of infection by pseudotyped viruses. (A) HOS cells
r VSV-G pseudotyped viruses produced with pHCMV-G (right). (B) HOS
rotein produced from pHTE-1 or a mutant envelope protein precurs
cleavage site and the fusion peptide of TM. Columns represent the mea
FIG. 4. The HTLV receptor is trypsin sensitive. PBMCs were pretrea
with the HTLV-1 envelope protein (pHTE-1), the HIV envelope prote
determined, and values from trypsin-treated cells were normalized to those of
of infection of duplicate assays, and the range of values is indicated.(Fig. 5) (Stein et al., 1987). These cells constitutively
express HIV-1 receptor CD4 and coreceptors CXCR4 and
CCR5 and carry the HTLV-1 long terminal repeat fused to
the b-galactosidase gene. To examine the mode of entry
y HTLV-1 envelope pseudotyped particles, the cells
ere pretreated with 30 mM ammonium chloride for
.5 h preinfection with or without an additional 19 h of
reatment postinfection (Fig. 5). A positive control used
articles pseudotyped with VSV-G, because this virus is
nown to enter cells through a pH-sensitive endocytic
nfected with HTLV-1 pseudotyped viruses produced with pHTE-1 (left)
ere infected with virus particles pseudotyped with the HTLV-1 envelope
ved from pHTE-1DSUTM, with alterations at the envelope precursor
s of infection of duplicate assays, and the range of values is indicated.
or without trypsin and then infected with viral particles pseudotyped
ADA), or VSV-G (pHCMV-G). Luciferase activity in cell lysates waswere i
cells wted with
in (pHXcell lysates from untreated cells. Columns represent the mean levels
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45HTLV RECEPTORpathway (Kielian and Jungerwirth, 1990). Infection by
HIV-1 was reduced ,10% by the ammonium chloride
treatments, which is consistent with previous observa-
tions (Stein et al., 1987). In contrast, infection by VSV-G
pseudotyped particles was reduced by .99% by ammo-
nium chloride treatment. Intermediate results were ob-
tained with HTLV-1 envelope pseudotyped particles, with
reductions of 53–78%. Similar experiments with ammo-
nium chloride and other endocytosis inhibitors could not
be performed in PBMCs due to the toxicity of these agents.
DISCUSSION
In vitro infection experiments suggested that the
HTLV-1 receptor has a wide species and cell type distri-
bution (Clapham et al., 1983; Hoxie et al., 1984; Krich-
baum-Stenger et al., 1987; Nagy et al., 1983; Watabe et
al., 1989; Yoshikura et al., 1984). Similarly, cell fusion
assays have also suggested that the HTLV-1 receptor is
widely expressed (Li et al., 1996; Okuma et al., 1999). The
urrent work extends the findings of Sutton and Littman
1996), using a sensitive pseudotype assay, to demon-
trate that the distribution of HTLV-1 receptor is wider
han appreciated in previous studies (Fig. 2). Thus most
f the cell lines reported in previous studies as not
nfectable by HTLV-1 were in fact susceptible to infection
FIG. 5. HTLV entry is partially sensitive to ammonium chloride. Mag
efore infection with or without an additional 19 h of treatment with am
TLV-1 envelope protein (pHTE-1), HIV envelope protein (pHXADA), o
alues of ammonium chloride-treated cells were normalized to those
nfection of duplicate assays, and the range of values is indicated.y the HTLV-1 envelope pseudotyped virus. The discrep-
ncy between these findings and fusion-based assays is
R
tost likely due to the higher sensitivity of the current
ssay. Low levels of entry through a non-fusion-based
athway may also be responsible for this finding.
The use of VSV-G pseudotyped particles provided an
mportant control for infection by pseudotyped particles
Fig. 2B). Thus one cell line, MDBK, was identified as
eing poorly susceptible to HTLV-1 infection, if it is in-
ectable at all. Although levels of infection of MDBK by
SV-G pseudotyped virus are depressed compared with
2 of the other cell lines tested, this activity level was
1000-fold above background levels, and higher than
hose of two other cell lines that were infectable by
TLV-1 envelope pseudotyped particles. This demon-
trates that postentry events required for reverse tran-
cription and expression of the SV40 promoter-luciferase
ndicator cassette are not compromised in these cells.
DBK cells were also not susceptible to HTLV-1 enve-
ope-mediated fusion (data not shown and Li et al., 1996).
he lack of infection of MDBK cells does not reflect a
eneral species restriction to HTLV-1 infection, because
ther bovine cell lines were susceptible to HTLV enve-
ope-mediated fusion (Li et al., 1996). The MDBK cells
ay lack either a critical component of the HTLV-1 re-
eptor or a coreceptor required for entry. Alternatively,
hey may possess a specific inhibitor of HTLV-1 infection.
cells were untreated or pretreated for 3.5 h with ammonium chloride
chloride post-infection (p.i.) with viral particles pseudotyped with the
(pHCMV-G). Luciferase activity in cell lysates was determined and
lysates from untreated cells. Columns represent the mean levels ofi-CCR5
monium
r VSV-Gecent data suggesting that access to the HTLV-1 recep-
or can be restricted by other cell surface molecules
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46 TREJO AND RATNERwould be consistent with this idea (Hildreth, 1998). Ex-
periments that examined somatic cell hybrids of MDBK
cells and susceptible target cells could discriminate
these possibilities. If MDBK cells are lacking a compo-
nent specific for HTLV-1 infection, these cells could be
suitable for genetic approaches aimed at determining
whether a specific human cDNA clone can confer infec-
tion on these cells.
The current work also addressed several candidate
molecules for the HTLV-1 receptor identified in previous
studies. The current work is in accord with previous
findings (Clapham et al., 1983) that the IL-2 receptor is
ot the HTLV-1 receptor, because nonlymphoid cells
e.g., HOS, HeLa, and 293T cells; Fig. 2) are susceptible
o infection. Furthermore, vascular cell adhesion mole-
ule-1 is probably not the receptor, because cells other
han endothelial cells can also be infected with HTLV-1
Hildreth et al., 1997). The 80-kDa protein expressed on
JAB-WH but not BJAB-CC84 cells (Agadjanyan et al.,
994) is also not likely the HTLV-1 receptor, because both
ell lines were infectable by HTLV-1 envelope
seudotyped viruses (Fig. 2). Furthermore, the 71-kDa
eat shock protein (Sagara et al., 1998) is also not likely
he HTLV-1 receptor, because antibodies to this protein
ad no affect on pseudotype virus infection (Fig. 3).
owever, the receptor is likely to be a cell surface pro-
ein, because trypsin treatment of susceptible target
ells markedly reduced infection by HTLV-1 envelope
seudotyped virus particles (Fig. 4).
The mechanism of entry by HTLV-1 after binding the
eceptor is also not understood. To determine whether a
H-sensitive endocytotic pathway is used, we examined
nhibition of HOS cell infection by ammonium chloride,
hich prevents acidification of the endosome. Cellular
ntry by HIV-1 is not pH sensitive (Stein et al., 1987), as
onfirmed in the current work (Fig. 5). In contrast, the
ntry of VSV-G pseudotyped particles was exquisively
ensitive to ammonium chloride (Kielian and Jungerwirth,
990; Marsh and Pelchen-Matthews, 1994). Studies with
TLV-1 envelope pseudotyped particles gave intermedi-
te results, with only partial inhibition by ammonium
hloride under these same conditions. The most likely
xplanation is that two distinct pathways of HTLV-1 entry
xist, which may represent a high-affinity receptor that
ses a pH-sensitive endocytotic pathway and a low-
ffinity receptor that uses a pH-insensitive endocytotic or
usion pathway. It is possible that only one or both of
hese pathways are present on cells of various tissues
nd species, accounting for the widespread expression
f the receptor. Additional studies of the entry mecha-
ism could use recently described transdominant dy-
amin mutants, to inhibit the formation of clathrin-coated
esicles (DeTulleo and Kirchhausen 1998).
In conclusion, the current study provides additional
nformation about the characteristics of the HTLV-1 re-
eptor that are critical for its definitive identification.
B
JMATERIALS AND METHODS
ell lines
HOS, 293T, HeLa, C127/LT, CHO, NIH 3T3, U87-MG,
DBK, CV-1, NRK, Tb11u, and QM7 cells were obtained
rom American Type Culture Collection (Rockville, MD).
JAB WH and BJAB CC84 were provided by Dr. M.
gadjanian (University of Pennsylvania). Tb1Lu cells
ere cultivated in modified Eagle’s medium with Earle’s
asic salt supplement, 10% fetal calf serum, 0.1 mM
onessential amino acids, 1 mM sodium pyruvate, 1 mM
L-glutamine, 100 U/ml penicillin, and 100 mg/ml strepto-
mycin. QM7 cells were cultivated in medium 199 with
Earle’s basic salt solution, 10% tryptose phosphate broth,
10% fetal calf serum, 1 mM sodium pyruvate, 1 mM
L-glutamine, 100 U/ml penicillin, and 100 mg/ml strepto-
mycin. All of the other cell lines were cultivated in Dul-
becco’s modified Eagle’s medium, 10% fetal calf serum, 1
mM sodium pyruvate, 100 U/ml penicillin, and 100 mg/ml
streptomycin. Human PBMCs were purified by Ficoll gra-
dient centrifugation from single donors and cultivated in
RPMI 1640 medium, 10% fetal calf serum, 1 mM glu-
tamine, 100 U/ml penicillin, 100 mg/ml streptomycin, and
0 U/ml IL-2 (provided by Chiron Corporation, Emeryville,
A). Magi-CCR5 cells were derived from stable transfec-
ion of a CCR5 expression clone into Magi cells, a HeLa
ell line stably transfected with human CD4 and a plas-
id containing the HIV-1 long terminal repeat fused to
he b-galactosidase gene (Hung et al., 1999).
lasmid construction
The HIVLuc1Env2 plasmid, pNL4-3SV40Luc1Env2,
as constructed from pGB108, provided by Dr. A. Pan-
aniban (University of Wisconsin). pGB108, a plasmid
ontaining the HIV-1 provirus from strain NL4-3 (Freed et
l., 1992), was digested with NheI to remove the SV40
romoter-hygromycin cassette present within the HIV-1
nv gene and to replace it with the NheI–XbaI fragment
f pGL3 (Promega, Madison, WI), containing the SV40
romoter-luciferase gene.
pHTE-1, provided by Dr. M.-C. Dokehlar, includes the
TLV-1 CR strain env gene, flanked by two HTLV-1 long
erminal repeats (Pique et al., 1990). pHTE-1DSUTM was
onstructed by replacing the SalI–NsiI fragment (nucle-
tides 493-1383) with a PCR amplified mutant frag-
ent constructed by primer overlap extension with the
ollowing oligonucleotides: A, 59-ACGCGTCGACGCTC-
AGGATATGACCCCATC-39; B, 59-TGCATGCATGGTCCT-
CAAGGATAACAAG-39; C, 59-CGTTCCCGCACAGCA-
AAGACGTGGCGGTCTGGCTTG-39; and D, 59-CAAGC-
AGACCGCCACGTCTTCTGCTGTGCGGGAACG-39. The
utant fragment includes the mutations R312T, V314E,
nd P315D and abolished an AgeI site and created a
bsI site (nucleotide 1131). pHCMV-G, provided by Dr.
.-K. Yee (City of Hope National Medical Center), includes
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47HTLV RECEPTORthe VSV-G gene under the regulation of a cytomegalovi-
rus promoter (Chen et al., 1996).
Infection with pseudotyped viruses
For production of pseudotyped viruses, 3 3 106 293
ells were plated overnight in a T75 flask and then
ransfected for 5 h with 50 ml of LipofectAMINE, 750 ml of
ptiMEM, and 10 mg of pNL4-3SV40Luc1Env2 with or
without 10 mg of pHTE-1, pHTE-1DSUTM, or pHCMV-G.
The cells were washed with OptiMEM and incubated for
12–16 h at 37°C and 5% CO2 with 8 ml of fresh medium
and 20 mM sodium butyrate and then for 60–72 h in 10 ml
of fresh medium. The culture supernatant was removed,
filtered through a 0.22-mm filter, and titered by an HIV-1
24 antigen ELISA (Abbott Laboratories, Chicago, IL).
he typical yield of virus particles was 1 mg/ml.
Freshly prepared virus was used to infect 3 3 106
target cells plated onto a 100-mm plate for 3 h at 37°C
and 5% CO2. The cells were washed and incubated with
resh medium for 48 h at 37°C and 5% CO2. The cells
were washed, and cell lysates were prepared in 100 ml of
luciferase assay buffer containing 0.1 M potassium phos-
phate, pH 7.8, 0.2% Triton X-100, and 1 mM fresh DTT.
Luciferase assays were performed on Optocomp I (MGM
Instruments).
For antibody inhibition assays, HOS cells were incu-
bated with 0.1% sodium azide, 10 mg/ml antibody to the
1-kDa heat shock protein (SC7298 or SC1049; Santa
ruz Biotechnology, Santa Cruz, CA), 10 mg/ml antibody
to the platelet-derived growth factor-b receptor (SC432;
Santa Cruz Biotechnology), or 10 mg/ml concentration of
ach of neutralizing anti-gp46 HTLV-1 antibodies PRH7A
nd PRH11A (provided by Dr. Steve Foung, Stanford Uni-
ersity; Hadlock et al., 1999). These antibodies blocked
0% of gp45 binding at 0.4 mg/ml and completely blocked
binding at 4 mg/ml (Hadlock et al., 1999). For trypsin
inhibition experiments, PBMCs were stimulated with
PHA-P (Difco) for 3 days and then preincubated with 500
mg/ml trypsin at 37°C and 5% CO2, washed, and infected
with viral pseudotypes. For ammonium chloride inhibi-
tion experiments, Magi-CCR5 was preincubated with 30
mM ammonium chloride with or without an additional
19 h of treatment postinfection.
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